{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelogenous+Leukemia%2C+Chronic%2C+Neoplasms%2C+Myelogenous+Leukemia%2C+Acute&page=2", "query": { "condition": "Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelogenous+Leukemia%2C+Chronic%2C+Neoplasms%2C+Myelogenous+Leukemia%2C+Acute&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T13:15:16.543Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00623870", "title": "A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "RO5045337", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2008-05", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-07-24T13:15:16.543Z", "location_count": 4, "location_summary": "Duarte, California • New Brunswick, New Jersey • New York, New York + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00623870" }, { "nct_id": "NCT01500161", "title": "Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Hodgkins Disease", "Non-Hodgkins Lymphoma", "Aplastic Anemia", "Multiple Myeloma", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Texas Oncology Cancer Center", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1, "start_date": "2011-11", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-07-24T13:15:16.543Z", "location_count": 1, "location_summary": "Amarillo, Texas", "locations": [ { "city": "Amarillo", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01500161" }, { "nct_id": "NCT06013423", "title": "Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia of Ambiguous Lineage", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Hematopoietic and Lymphatic System Neoplasm", "Mixed Phenotype Acute Leukemia", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm", "Non-Hodgkin Lymphoma", "Chronic Myeloid Leukemia, BCR-ABL1 Positive" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspirate", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Diagnostic Imaging", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Umbilical Cord Blood Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "65 Years", "sex": "ALL", "summary": "6 Months to 65 Years" }, "enrollment_count": 54, "start_date": "2024-07-23", "completion_date": "2032-10-31", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-07-24T13:15:16.543Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06013423" }, { "nct_id": "NCT03959241", "title": "TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Leukemia", "Chronic Myelogenous Leukemia (CML)", "Myelodysplasia", "Lymphoma" ], "interventions": [ { "name": "Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide", "type": "PROCEDURE" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 431, "start_date": "2019-06-25", "completion_date": "2022-09-19", "has_results": true, "last_update_posted_date": "2024-04-04", "last_synced_at": "2026-07-24T13:15:16.543Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03959241" }, { "nct_id": "NCT00301951", "title": "Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 7, "start_date": "2004-09", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2017-10-12", "last_synced_at": "2026-07-24T13:15:16.543Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00301951" }, { "nct_id": "NCT01894477", "title": "Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia in Remission", "Chronic Myelomonocytic Leukemia", "Minimal Residual Disease", "Myelodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable" ], "interventions": [ { "name": "Allogeneic Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Treosulfan", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 102, "start_date": "2013-11", "completion_date": "2022-06", "has_results": true, "last_update_posted_date": "2021-06-03", "last_synced_at": "2026-07-24T13:15:16.543Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01894477" }, { "nct_id": "NCT00038805", "title": "Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Mylotarg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "55 Years to 75 Years" }, "enrollment_count": 3, "start_date": "2001-05", "completion_date": "2004-11", "has_results": false, "last_update_posted_date": "2018-10-31", "last_synced_at": "2026-07-24T13:15:16.543Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00038805" }, { "nct_id": "NCT00469729", "title": "Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hematologic Malignancies", "Acute Myeloid Leukemia", "Lymphoid Leukemia", "Chronic Myeloid Leukemia", "Hodgkin's Disease", "Non-Hodgkin's Lymphoma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "StemEx®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gamida Cell -Teva Joint Venture Ltd.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "12 Years to 55 Years" }, "enrollment_count": 101, "start_date": "2007-10", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2015-07-10", "last_synced_at": "2026-07-24T13:15:16.543Z", "location_count": 16, "location_summary": "Los Angeles, California • Orange, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00469729" }, { "nct_id": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome (MDS)", "Chronic Myelomonocytic Leukemia (CMML)", "Myeloproliferative Neoplasms (MPNs)" ], "interventions": [ { "name": "LY3410738", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2020-11-19", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-07-24T13:15:16.543Z", "location_count": 12, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04603001" }, { "nct_id": "NCT03320642", "title": "GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Calcineurin inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2018-02-27", "completion_date": "2022-02-17", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-07-24T13:15:16.543Z", "location_count": 9, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Maywood, Illinois + 6 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03320642" } ] }